Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14976505 | 0.83 | NPC1 (0.38) | NR4A2NPC1RAB9AKMT2ADHODH | |
| SCHEMBL28007987 | 0.80 | PDE2A (0.49) | PDE2APDE10APTGS2MKNK1MKNK2 | |
| SCHEMBL27868401 | 0.78 | CCR1 (0.44) | L3MBTL1NR4A2KMT2A | |
| SCHEMBL9523594 | 0.76 | NPC1 (0.40) | PDE2APDE10ANPC1RAB9AKMT2A | |
| SCHEMBL5100088 | 0.76 | MKNK1 (0.39) | PDE2APDE10AMKNK1MKNK2TDO2 | |
| SCHEMBL2316029 | 0.74 | GRIN2B (0.34) | NPC1RAB9A | |
| SCHEMBL14976333 | 0.73 | RORB (0.38) | L3MBTL1NR4A2KMT2A | |
| SCHEMBL2320151 | 0.73 | NUDT1 (0.32) | L3MBTL1NPC1RAB9A | |
| SCHEMBL432357 | 0.73 | GABRP (0.41) | PDE2APDE10ANPC1RAB9A | |
| SCHEMBL6682355 | 0.72 | CYP2A6 (0.40) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | EDNRA, OXGR1, EDF1 | PDE2A 422/4885PDE10A 1715/4885PTGS1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.